Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.46 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 6/20 | 0.45 |
| ▸ | BCDIN3D | Q7Z5W3 | 3/20 | 0.44 |
| ▸ | BCL6 | P41182 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301912 | 0.85 | CTSC (0.57) | CDK1CTSC | |
| SCHEMBL17915996 | 0.85 | AURKA (0.55) | AURKASTK17ADHODHCDK1JAK3 | |
| SCHEMBL301785 | 0.85 | AURKA (0.57) | AURKASTK17ABCL6JAK3JAK2 | |
| SCHEMBL270778 | 0.83 | AURKA (0.52) | AURKAFLT3STK17ADHODHCDK1 | |
| SCHEMBL10259353 | 0.82 | STK17A (0.62) | AURKASTK17ABCL6STK17B | |
| SCHEMBL301484 | 0.82 | EGFR (0.57) | AURKAFLT3CAMK2DSTK17ACDK1 | |
| SCHEMBL301488 | 0.81 | STK17A (0.53) | AURKASTK17ABCL6DHODHJAK3 | |
| SCHEMBL28051487 | 0.78 | KCNH3 (0.47) | FLT3PRKCDCAMK2BCAMK2GCAMK2D | |
| SCHEMBL270663 | 0.78 | DHODH (0.48) | AURKADHODHEGFR | |
| SCHEMBL303133 | 0.77 | SYK (0.49) | AURKASTK17ABCL6JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | AURKA 745/4885FLT3 8/4885PRKCD 2020/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | AURKA 75/4885FLT3 7/4885PRKCD 1515/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | AURKA 3934/4885FLT3 481/4885PRKCD 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.